PTAB Rules in Favor of Finnegan Client Biogen, Denying Hedge Fund’s IPR Petition

FOR IMMEDIATE RELEASE
September 2, 2015

WASHINGTON, DC—On September 2, 2015, the Patent Trial and Appeal Board (PTAB) declined to institute an inter partes review (IPR) of a patent held by Finnegan client Biogen MA that covers the multiple sclerosis drug Tecfidera®. The IPR petition was filed by the Coalition for Affordable Drugs V (CFAD), a group of hedge funds managed by Kyle Bass.

In its written decision, the PTAB denied institution on all grounds, stating that petitioner CFAD failed to establish a likelihood that any of the challenged claims were unpatentable. This decision comes just three weeks after Finnegan filed a preliminary response on behalf of patent owner Biogen.

The case is Petition for Inter Partes Review by Coalition for Affordable Drugs V LLC, IPR2015-01136, PTAB.

Contacts
James B. Monroe, Managing Partner 
james.monroe@finnegan.com

About Finnegan

Finnegan is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices all aspects of patent, trademark, copyright, and trade secret law, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to European patent oppositions, international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. Follow us on LinkedIn and Twitter.